Survival difference according to mutation status in a prospective cohort study of Australian patients with metastatic non-small-cell lung carcinoma-Reference-Cited by-同舟云学术

Survival difference according to mutation status in a prospective cohort study of Australian patients with metastatic non-small-cell lung carcinoma

Published:2018-01 Issue:1 Volume:48 Page:37-44
ISSN:1444-0903
Container-title:Internal Medicine Journal
language:en
Short-container-title:Intern Med J

Author:

Tan Lavinia¹^ORCID,Alexander Marliese¹²,Officer Ann¹,MacManus Michael³⁴,Mileshkin Linda¹⁴,Jennens Ross¹,Herath Dishan¹,de Boer Richard¹,Fox Stephen B⁵⁴,Ball David³⁴,Solomon Benjamin¹⁴

Affiliation:

1. Department of Medical Oncology; Peter MacCallum Cancer Centre; Melbourne Victoria Australia

2. Department of Epidemiology and Preventative Medicine; Monash University; Melbourne Victoria Australia

3. Division of Radiation Oncology; Peter MacCallum Cancer Centre; Melbourne Victoria Australia

4. Sir Peter MacCallum Department of Oncology; The University of Melbourne; Melbourne Victoria Australia

5. Department of Pathology; Peter MacCallum Cancer Centre; Melbourne Victoria Australia

Publisher

Wiley

Subject

Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/imj.13491/fullpdf

Reference32 articles.

1. Non-small cell lung cancer: epidemiology, risk factors, treatment and survivorship;Molina;Mayo Clin Proc,2008

2. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer;Schiller;N Engl J Med,2002

3. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies;Li;J Clin Oncol,2013

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Geographic differences in lung cancer: focus on carcinogens, genetic predisposition, and molecular epidemiology;Therapeutic Advances in Medical Oncology;2024-01

2. Optimising tissue acquisition and the molecular testing pathway for patients with non-small cell lung cancer: A UK expert consensus statement;Lung Cancer;2022-10

3. Expert opinion on NSCLC small specimen biomarker testing — Part 1: Tissue collection and management;Virchows Archiv;2022-07-20

4. Expert opinion on NSCLC small specimen biomarker testing — Part 2: Analysis, reporting, and quality assessment;Virchows Archiv;2022-07-20

5. Demographic and Clinical Outcomes of Brazilian Patients With Stage III or IV Non–Small-Cell Lung Cancer: Real-World Evidence Study on the Basis of Deterministic Linkage Approach;JCO Global Oncology;2021-09